HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome.

AbstractBACKGROUND:
The need for diagnostic biomarkers of cognitive decline is particularly important among aging adults with Down syndrome (DS). Growing empirical support has identified the utility of plasma derived biomarkers among neurotypical adults with mild cognitive impairment (MCI) and Alzheimer's disease (AD); however, the application of such biomarkers has been limited among the DS population.
OBJECTIVE:
This study aimed to investigate the cross-sectional diagnostic performance of plasma neurofilament light chain (Nf-L) and total-tau, individually and in combination among a cohort of DS adults.
METHODS:
Plasma samples were analyzed from n = 305 (n = 225 cognitively stable (CS); n = 44 MCI-DS; n = 36 DS-AD) participants enrolled in the Alzheimer's Biomarker Consortium -Down Syndrome.
RESULTS:
In distinguishing DS-AD participants from CS, Nf-L alone produced an AUC of 90%, total-tau alone reached 74%, and combined reached an AUC of 86%. When age and gender were included, AUC increased to 93%. Higher values of Nf-L, total-tau, and age were all shown to be associated with increased risk for DS-AD. When distinguishing MCI-DS participants from CS, Nf-L alone produced an AUC of 65%, while total-tau alone reached 56%. A combined model with Nf-L, total-tau, age, and gender produced an AUC of 87%. Both higher values in age and total-tau were found to increase risk for MCI-DS; Nf-L levels were not associated with increased risk for MCI-DS.
CONCLUSION:
Advanced assay techniques make total-tau and particularly Nf-L useful biomarkers of both AD pathology and clinical status in DS and have the potential to serve as outcome measures in clinical trials for future disease-modifying drugs.
AuthorsMelissa E Petersen, Michael S Rafii, Fan Zhang, James Hall, David Julovich, Beau M Ances, Nicole Schupf, Sharon J Krinsky-McHale, Mark Mapstone, Wayne Silverman, Ira Lott, William Klunk, Elizabeth Head, Brad Christian, Tatiana Foroud, Florence Lai, H Diana Rosas, Shahid Zaman, Mei-Cheng Wang, Benjamin Tycko, Joseph H Lee, Benjamin Handen, Sigan Hartley, Juan Fortea, Sid O'Bryant, Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS)
JournalJournal of Alzheimer's disease : JAD (J Alzheimers Dis) Vol. 79 Issue 2 Pg. 671-681 ( 2021) ISSN: 1875-8908 [Electronic] Netherlands
PMID33337378 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Neurofilament Proteins
  • neurofilament protein L
  • tau Proteins
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease (blood, complications, diagnosis)
  • Biomarkers (blood)
  • Cognitive Dysfunction (blood, complications, diagnosis)
  • Cross-Sectional Studies
  • Down Syndrome (complications)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neurofilament Proteins (blood)
  • tau Proteins (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: